SAN DIEGO--(BUSINESS WIRE)--Mar 30, 2026--
Certis Oncology, an AI-enabled translational science company, today announced the launch of Certis Oncology Intelligence ®, an integrated platform designed to generate data-driven insights into therapeutic response by combining predictive modeling, agentic AI-enabled biological data exploration, and functional validation in clinically relevant cancer models.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330264289/en/
Certis Oncology Intelligence represents a new approach to translational research—one that connects computational prediction with real-world biological evidence in a continuous learning system.
“One of the central challenges in oncology drug development is that we generate enormous amounts of data, but struggle to translate that into reliable predictions of therapeutic response,” said Peter Ellman, Certis President and CEO. “Certis Oncology Intelligence was built to close that gap—linking prediction, biological context, and experimental validation into a system that continuously learns and improves over time.”
A Three-Layer Translational Intelligence System
Certis Oncology Intelligence is a secure, multi-tenant, closed loop system that integrates three data layers:
Unlocking the Value of Translational Data
The platform is designed to help pharmaceutical and biotechnology companies:
By enabling organizations to extract new insights from existing data while continuously generating new evidence, Certis Oncology Intelligence offers a scalable foundation for more predictive and data-driven oncology development.
Availability
Certis Oncology Intelligence is available to pharmaceutical and biotechnology partners through licensing and collaborative engagements.
About Certis Oncology
Certis Oncology is an AI-enabled translational science company dedicated to realizing the promise of precision oncology. At the core of the company’s platform is CertisAI™, a patented machine-learning system designed to model the relationships between drug chemistry and tumor biology. By integrating computational modeling with functional testing in clinically relevant patient-derived tumor models, Certis generates Oncology Intelligence®—highly predictive therapeutic response data that helps pharmaceutical companies select better drug candidates, design smarter development strategies, and improve the probability of clinical success.
Founded in 2016, Certis operates a CLIA-certified, AAALAC- and OLAW-accredited laboratory in San Diego’s Sorrento Valley life sciences hub.
A Continuous Learning System for Oncology: By connecting prediction, exploration, and validation, Certis Oncology Intelligence creates a closed-loop system: This approach enables translational teams to move beyond static datasets and fragmented workflows, transforming both historical and newly generated data into a continuously evolving body of knowledge.
NEW YORK--(BUSINESS WIRE)--Mar 30, 2026--
Elysian, the first AI-native Third-Party Administrator (TPA) purpose-built for complex commercial claims, today announced the appointment of Zack Moy as Chief Technology Officer. Moy has spent 15 years working on a specific class of engineering problem: how to give structure to unstructured data so that knowledge workers can make better, faster decisions. At Elysian, that work meets its most consequential application yet. Commercial claims generate dense, ambiguous information from dozens of sources simultaneously. The ability to process that information accurately, at speed, and in a form that supports expert judgment is what separates outcomes at Elysian from outcomes anywhere else in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330216243/en/
Moy began his engineering career at Google before co-founding Pattern, an enterprise tool for organizing and acting on complex, unstructured information, acquired by Workday. At Workday, he served as a founding team member of Workday Cloud Platform and rose to Director of Engineering for Workday Extend, leading the development of infrastructure that enterprise organizations use to build and operate mission-critical software at scale. He went on to co-found Afterword, an AI platform serving 20,000+ families through funeral home operations, leading technology in a domain where the margin for error carries direct human consequences. After this, Moy founded Waystone Labs, a research lab dedicated to agentic workflow design.
Across his career, Moy has consistently taken on the same class of problem at greater levels of scale and consequence, building software infrastructure for knowledge workers operating in high-pressure environments where accuracy determines outcomes. His experience is directly applicable to the technical demands of complex commercial claims administration, where Elysian's platform must perform reliably across an enormous volume of ambiguous, time-sensitive information.
"The technical challenge at Elysian is not a simple one. We are building AI infrastructure that has to perform accurately and reliably on the most complex claims in commercial insurance, while scaling a business and deepening client relationships simultaneously. Zack has done this kind of work before, at multiple companies, across different contexts. He has the engineering depth to lead the platform forward and the founder instincts to know what matters as we grow."
said Grace Hanson, Founder and CEO of Elysian.
As CTO, Moy will oversee Elysian’s technical strategy and the continued development of its proprietary Claim Conductor platform. He will work in close collaboration with Head of Product Martin Schwitzner, as well as Founding Engineer, Dylan Hanson, to advance the technical capabilities that underpin Elysian's claims outcomes.
"Commercial claims are informationally complex in ways most AI systems are not designed to handle. Medical records, legal filings, coverage analysis, and live adjuster judgment all run in parallel, under time pressure. Elysian has approached this problem with real technical seriousness. The knowledge infrastructure underlying the platform reflects how expert adjusters actually think and what good outcomes actually require. That is what makes this work worth doing."
said Zack Moy, Chief Technology Officer of Elysian.
Moy's appointment underscores Elysian's commitment to building a technology organization capable of delivering on the complexity of commercial claims at scale. Among its accolades, the company was named to the CB Insights Insurtech Top 50 list, and won the State Farm Startup Pitch Competition at ITC Vegas in 2025. Most recently, Elysian was selected for Lloyd's Lab Cohort 16, a globally competitive program ranked the number-one insurance-focused startup hub by the Financial Times. Under Moy’s leadership, Elysian is well-positioned to advance its platform capabilities and significantly deepen its impact across the commercial insurance market.
About Elysian
Founded in late 2024, Elysian is the first AI-native TPA proven to achieve superior outcomes in commercial insurance. Elysian combines AI-orchestrated claims processing with elite adjusting talent to handle complex commercial claims with unprecedented efficiency. Intrinsic multimodal AI-agent orchestration, purpose-built machine learning, statistical optimization and autonomous decision systems deliver precise insights that empower adjusters to make the right decisions. Learn more at www.elysian.is
Zack Moy, Chief Technology Officer, Elysian
